within Pharmacolibrary.Drugs.ATC.L;

model L04AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.038 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.00161,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018666666666666668,
    Tlag           = 2400
  );

  annotation(Documentation(
    info ="<html><body><p>Tacrolimus is an immunosuppressant macrolide used primarily to prevent organ transplant rejection and to treat certain autoimmune diseases. It acts by inhibiting calcineurin, thus suppressing T-lymphocyte activation. It is approved and remains widely used in clinical practice, particularly for kidney, liver, and heart transplant recipients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters reported for adult kidney transplant recipients following oral administration in the early post-transplant period, population containing both sexes.</p><h4>References</h4><ol><li><p>Venkataramanan, R, Swaminathan, A, Prasad, T, Jain, A, Zuckerman, S, Warty, V, McMichael, J, Lever, J, Burckart, G, &amp; Starzl, T (1995). Clinical pharmacokinetics of tacrolimus. <i>Clinical pharmacokinetics</i> 29(6) 404–430. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199529060-00003&quot;>10.2165/00003088-199529060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8787947/&quot;>https://pubmed.ncbi.nlm.nih.gov/8787947</a></p></li><li><p>Martial, LC, Biewenga, M, Ruijter, BN, Keizer, R, Swen, JJ, van Hoek, B, &amp; Moes, DJAR (2021). Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British journal of clinical pharmacology</i> 87(11) 4262–4272. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14842&quot;>10.1111/bcp.14842</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33786892/&quot;>https://pubmed.ncbi.nlm.nih.gov/33786892</a></p></li><li><p>Lee, KW, Kim, TH, Lee, JB, Kim, KS, Park, JB, Gershkovich, P, Yoo, SD, Shin, S, Shin, BS, &amp; Kim, SJ (2019). Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of pharmacological sciences</i> 139(2) 65–71. DOI:<a href=&quot;https://doi.org/10.1016/j.jphs.2018.05.013&quot;>10.1016/j.jphs.2018.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30573325/&quot;>https://pubmed.ncbi.nlm.nih.gov/30573325</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AD02;
